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Abstract. Infantile hemangiomas (IHs) are non-malignant, 
largely cutaneous vascular tumors affecting approximately 
5-10% of children to varying degrees. During the first year 
of life, these tumors are strongly proliferative, reaching an 
average size ranging from 2 to 20 cm. These lesions subse-
quently stabilize, undergo a spontaneous slow involution and 
are fully regressed by 5 to 10 years of age. Systemic treatment 
of infants with the non-selective β-adrenergic receptor blocker, 
propranolol, has demonstrated remarkable efficacy in reducing 
the size and appearance of IHs. However, the mechanism by 
which this occurs is largely unknown. In this study, we sought 
to understand the molecular mechanisms underlying the 
effectiveness of β blocker treatment in IHs. Our data reveal 
that propranolol treatment of IH endothelial cells, as well as a 
panel of normal primary endothelial cells, blocks endothelial 
cell proliferation, migration, and formation of the actin cyto-
skeleton coincident with alterations in vascular endothelial 
growth factor receptor-2 (VEGFR-2), p38 and cofilin signaling. 
Moreover, propranolol induces major alterations in the protein 
levels of key cyclins and cyclin-dependent kinase inhibitors, 
and modulates global gene expression patterns with a particular 
affect on genes involved in lipid/sterol metabolism, cell cycle 
regulation, angiogenesis and ubiquitination. Interestingly, the 
effects of propranolol were endothelial cell-type independent, 
affecting the properties of IH endothelial cells at similar 
levels to that observed in neonatal dermal microvascular 
and coronary artery endothelial cells. This data suggests that 
while propranolol markedly inhibits hemangioma and normal 
endothelial cell function, its lack of endothelial cell specificity 
hints that the efficacy of this drug in the treatment of IHs may 
be more complex than simply blockage of endothelial function 
as previously believed.
Introduction
Infantile hemangiomas (IHs) are the most common benign 
tumors in infancy affecting 5-10% of the population, and are 
largely composed of densely packed over-proliferating capil-
laries with high cellular density and the absence of an open 
lumen. These lesions are most prevalent in Caucasian children 
and are three times more common in female infants than male. 
The head and neck region is the most frequently involved area 
(60%), followed by the trunk (25%) and the extremities (15%), 
and these tumors exhibit a non-random distribution largely 
correlating with regions of embryological fusion (1). IHs have a 
predictable natural history, arising soon after birth to undergo 
a significant proliferative phase during the first year of life, 
followed by gradual involution over several years. Regression 
is complete in 50% of 5-year-old patients and 90% of 9-year-
old patients. Because these tumors spontaneously regress and 
(for the majority of lesions) produce no long-term scarring, 
most children with IHs require no treatment. Despite their 
self-limiting course, in approximately 10% of cases depending 
on their anatomical site and/or size, there can be serious or life 
threatening complications requiring immediate intervention. 
The classical approaches for treating complicated IHs include 
the use of systemic or intralesional corticosteroids, chemo-
therapeutic agents such as vincristine, laser therapy, surgical 
resection or a combination of these treatments. The recent 
serendipitous discovery of β blockers as an effective therapy 
for IHs has revolutionized management of IHs to become the 
current gold standard (2).
Propranolol treatment of infantile hemangioma 
endothelial cells: A molecular analysis
JESSICA STILES1,  CLARISSA AMAYA1,  ROBERT PHAM2,  REBECCA K. ROWNTREE1,  MARY LACAZE3,  
ARLYNN MULNE3,  JOYCE BISCHOFF4,  VICTOR KOKTA5,  LAURA E. BOUCHERON2,  
DIANNE C. MITCHELL1  and  BRAD A. BRYAN1
1Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, 
El Paso, TX; 
2Klipsch School of Electrical and Computer Engineering, New Mexico State University, Las Cruces, NM;  
3Department of Pediatrics, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, 
El Paso, TX; 
4Vascular Biology Program and Department of Surgery, Children's Hospital Boston and 
Harvard Medical School, Boston, MA, USA;  
5Department of Pathology, CHU Sainte-Justine, 
University of Montreal, Montreal, Quebec, Canada
Received June 21, 2012;  Accepted July 27, 2012
DOI: 10.3892/etm.2012.654
Correspondence to: Dr Brad A. Bryan, Department of Biomedical 
Sciences, Paul L. Foster School of Medicine, Texas Tech University 
Health Sciences Center, Center of Excellence in Cancer Research, 
5001 El Paso Drive, El Paso, TX 79905, USA
E-mail: brad.bryan@ttuhsc.edu
Key words: infantile hemangioma, propranolol, endothelial cells, 
angiogenesisSTILES et al:  PROPRANOLOL TREATMENT OF INFANTILE HEMANGIOMA ENDOTHELIAL CELLS 595
Propranolol, which is administered systemically in pedi-
atric patients with IHs, is a non-selective β-adrenergic receptor 
antagonist that blocks the action of epinephrine and norepi-
nephrin. This drug has been shown to suppress angiogenesis 
via inhibition of proliferation, migration, barrier function, and 
induction of apoptosis in primary cultures of normal epithelial 
cells (3-6). The molecular mechanism of action for propranolol 
includes disrupting the epinephrine and norpinephrine regula-
tion of cyclic AMP production, actin cytoskeletal dynamics 
and release of atherogenesis regulators (7-9). Only recently 
have investigations into the precise roles of propranolol in 
IHs revealed that this therapy blocks hemangioma endothelial 
growth and this effect may be through suppressing the produc-
tion of nitric oxide and HIF1α regulation of vascular endothelial 
growth factor (VEGF) expression (10,11). Perplexingly, it is 
unknown how propranolol preferentially inhibits the growth of 
IHs, while spares the formation of new blood vessels necessary 
for growth and development of the infant. In this study, we 
sought to further evaluate the molecular mechanisms by which 
propranolol exerts its effects on human IH endothelial cells 
(HemECs). Furthermore, we compared the biological response 
of HemECs treated with propranolol to that of normal human 
endothelial cells treated with propranolol. Our data indicate 
that propranolol disrupts cell proliferation through modula-
tion of key cell cycle regulators and blocks cell migration via 
alterations in the activation status of proteins essential for 
cytoskeletal dynamics. We further showed via microarray 
analysis that propranolol leads to large-scale changes in global 
gene expression, particularly in genes involved in lipid/sterol 
metabolism, cell cycle regulation, angiogenesis and post-trans-
lational modification. Interestingly, our data indicate that the 
effects of propranolol on HemECs are similar to that observed 
in normal endothelial cells, suggesting that this drug is not 
specific to HemECs.
Materials and methods
Cell lines and culture conditions. HemECs were previously 
isolated from proliferating-phase IH specimens collected from 
female infants (12). Primary cultures of neonatal human dermal 
microvascular endothelial cells (HDMVECs) and human 
coronary artery endothelial cells (HCAECs) were purchased 
from ATCC. These cell lines were cultured in vascular cell 
basal media (ATCC #PCS-100-030) and supplemented with 
0.2% bovine brain extract, 5 ng/ml human epidermal growth 
factor, 10 mM L-glutamine, 0.75 U/ml heparin sulfate, 1 µg/  ml 
hydrocortisone, 50 µg/ml ascorbic acid, 2% fetal bovine serum 
and penicillin/streptomycin. For all experiments cell lines 
were used at <10 passages.
RT-PCR. RNA was isolated from cells using the Ambion 
Purelink Mini kit according to the manufacturer's direc-
tions. qRT-PCR was performed on an ABI7900HT RT-PCR 
system using TaqMan assays with predesigned primer sets for 
the genes of interest (Invitrogen). All RT-PCR experiments 
were performed in triplicate. Data shown are the average 
RQ value ± standard deviation of 4 replicates.
Western blot analysis. Cell lysates were collected after 48 h 
treatment and subjected to SDS-PAGE on gradient (4-15%) 
gels and subsequently transferred to PVDF for western 
blotting. p-vascular endothelial growth factor receptor-2 
(VEGFR-2) (Cell Signaling #2478), VEGFR-2 (Cell Signaling 
#2479), p-p38 (Cell Signaling #4511), p-p44/42 (Cell Signaling 
#4370), p-SAPK/JNK (Cell Signaling #4668), p-ATF2 (Cell 
Signaling #5112), actin (Santa Cruz #SC47778), cyclin A1 
(Abcam #ab13337), cyclin A2 (Abcam #7956), cyclin B2 
(Abcam #18250), cyclin D1 (Cell Signaling #2978), cyclin D2 
(Cell Signaling #3741), cyclin D3 (Cell Signaling #2936), 
cyclin E1 (Cell Signaling #4129), p15 (Cell Signaling #4822), 
p21 (Cell Signaling #2947), p27 (Cell Signaling #3698), 
cleaved caspase-9 (Cell Signaling #9509), cleaved caspase-3 
(Cell Signaling #9664), p-FAK (Cell Signaling #3283), 
p-cofilin (Cell Signaling #3313), cofilin (Cell Signaling #3318), 
p-ERM (Cell Signaling #3149), ERM (Cell Signaling #3142), 
p-MYPT1 (Cell Signaling #4563) and MYPT1 (Cell Signaling 
#2634) antibodies were used at a 1:1000 dilution, followed by 
incubation with 1:1000 HRP-conjugated anti-mouse or anti-
rabbit antibodies (as appropriate). Proteins were detected using 
Supersignal West Dura Extended Duration Substrate (Thermo 
Scientific) and digitally captured using a GE Image Quant 
LAS4000 imaging system.
Proliferation assay. Cells were plated at subconfluent density 
and subjected to the indicated treatments for 48 h. Images 
from 5 independent areas were collected at 1-h intervals using 
a Nikon Biostation CT time lapse imaging robot. Changes in 
cell density were calculated every 24 h by counting the number 
of cells in the selected field of vision. Data shown represent the 
average of 5 independent areas ± the standard deviation.
Flow cytometry. Cells were treated as indicated, trypsinized, 
and fixed in 70:30 ethanol:phosphate-buffered saline overnight. 
Cells were then stained with 200 µg/ml ethidium bromide plus 
20 µg/ml RNase A and incubated overnight. DNA content 
was analyzed using an Accuri C6 flow cytometer. Data shown 
are representative of at least 3 independent experiments. 
Quantitative analysis of DNA content was performed using 
CFlow Plus software (Accuri) and is the average of triplicate 
data points.
Live/dead assay. Cells were treated as indicated, stained for 
10 min with 5 µg/ml Hoechst and 5 µg/ml propidium iodide, 
and washed 3 times in PBS. A Nikon C2SI scanning laser 
confocal microscope was used to image the red and blue chan-
nels. Percent apoptosis (A) was calculated by the following 
formula: A = (number of red cells/number of blue cells) x 100. 
The data presented is the average of triplicates.
Migration assay. Confluent cultures were treated as indi-
cated, scratch wounded, and the progress of ‘healing’ of the 
wound was monitored using a Nikon Biostation CT time lapse 
imaging robot. Migration speed was calculated by monitoring 
the movement of the ‘wound’ toward its center at each hour 
over a 12-h period.
Immunofluorescence and cytoskeletal organization calcula-
tions. Cells were grown on glass coverslips, treated as indicated 
and fixed in 4% paraformaldehyde. Then, the coverslips were 
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incubated with 1:200 of the p-FAK antibody and detected 
with fluorescently conjugated secondary antibodies. Actin 
microfilaments were detected by staining with Rhodamine-
conjugated phalloidin, and cell nuclei were detected with 
4',6-diamidino-2-phenylindole (DAPI). Immunofluorescent 
images were captured as z-stacks using a Nikon C2SI scan-
ning laser confocal microscope. Image analysis of cytoskeletal 
organization included calculating the actin stress fiber correla-
tion and binarizing this correlation image to determine fiber 
lengths using the FiberScore algorithm (13).
Microarray analysis. Total RNA was amplified and biotin-
labeled using Illumina TotalPrep RNA Amplification kit 
(Ambion). A total amount of 750 ng of biotinylated aRNA 
was then briefly heat-denatured and loaded onto expres-
sion arrays to hybridize overnight. Following hybridization, 
arrays were labeled with Cy3-streptavidin and imaged on the 
Illumina ISCAN. Intensity values were transferred to Agilent 
GeneSpring GX microarray analysis software and data were 
filtered based on the quality of each call. Statistical relevance 
was determined using ANOVA with a Benjamini Hochberg 
FDR multiple testing correction (p<0.05). Data were then 
limited by fold change analysis to statistically relevant data 
points demonstrating a 2-fold or more change in expression.
Results
β-adrenergic receptor expression in HemECs and IHs. The 
presence of β-adrenergic receptors on normal human endo-
thelial cells has been previously confirmed (14). However, 
despite the extensive use of systemic propranolol as an anti-IH 
agent, the expression of the three known β-adrenergic recep-
tors in endothelial cells isolated from these benign tumors 
is unknown. Using RT-PCR, we evaluated the steady state 
mRNA expression of the three known β-adrenergic receptors 
(ADRB1, ADRB2 and ADRB3) in cultured HemECs. Our 
data revealed that ADRB1 and 2, although not ADRB3, were 
expressed in HemECs (Fig. 1). Moreover, similar results were 
observed for both HDMVECs and HCAECs, with equivalent 
levels of each receptor across the three endothelial cell lines.
Propranolol disrupts cell cycle progression. Despite the exten-
sive use of propranolol, many of the mechanisms of action 
of this drug on IHs have been inferred from its effects on 
normal endothelial cells (7-9). Recent studies have suggested 
that propranolol may inhibit IHs by suppressing production 
of nitric oxide and HIF1α signaling (10,11). However, the 
signaling intermediates and many of the downstream effec-
tors which modulate its action on IHs are largely unknown. 
To elucidate the molecular components at play following 
propranolol-induced inhibition of HemEC proliferation, we 
first examined the growth rates of HemECs, HDMVECs and 
HCAECs after treatment with a dose curve of propranolol. 
Our data indicate that the IC50 for propranolol-induced inhi-
bition of proliferation was ~50 µM for all three cell types 
(Fig. 2A and B), therefore for all subsequent experiments in 
this study we continued to use this concentration. Moreover, 
cell cycle analysis on the panel of endothelial cells using flow 
cytometry revealed that propranolol indiscriminately induced 
an increase in the proportion of cells in the G1 phase of the cell 
cycle, while reducing the proportion of cells in the S and G2/M 
phases (Fig. 2C, Table I). Equivalent results were observed in 
HDMVECs and HCAECs (Table I). To address the effects 
of propranolol on HIHEC proliferation, we analyzed the 
expression/activation status of a number of proteins involved 
in regulating proliferation. VEGFR-2 is a strong mitogenic 
regulator of endothelial cells that shows aberrant constitutive 
activation in HemECs (15), and its phosphorylation is report-
edly blocked following propranolol treatment (5). Indeed, the 
24-h treatment of HemECs with 50 mM propranolol resulted 
in sharply decreased VEGFR-2 phosphorylation (Fig. 2D). 
The mitogen activated protein kinases (MAPKs) are direct 
downstream effectors of VEGFR-2 regulating VEGF-induced 
endothelial proliferation. We tested the activation status of 
p38, p44, p42, SAPK, JNK, and the downstream effector 
ATF4 in HemECs experiencing 24 h of propranolol treatment. 
Of the proteins tested, the stress activated p38 (but not the 
stress activated SAPK or JNK) was the only one that exhibited 
a significant change in phosphorylation following propranolol 
treatment of HemECs (Fig. 2D). These data suggest that 
despite the inhibition of VEGFR-2 noted following the treat-
ment, the major proliferative MAPKs such as p44 and p42 
were not affected by propranolol treatment in HemECs. As 
flow cytometry analysis indicated that propranolol induced 
alterations in cell cycle progression, we performed western 
blot analysis on a panel of cell cycle regulators, discovering 
that this drug decreases the expression of key cyclin proteins 
(cyclins A1, A2, B2, D2 and D3) and increases the expression 
of important cell cycle inhibitors (p15, p21 and p27) (Fig. 2E). 
No change in the expression of Cdk2 or Cdk4 was observed 
following the treatment. These alterations in key cell cycle 
regulators likely account for propranolol-induced alterations 
in HemEC proliferation.
It is speculated that propranolol may increase apoptosis of 
IHs. To determine whether this drug affects apoptosis, we 
treated HemECs, HDMVECs and HCAECs with 50 µM 
propranolol for 3 days. As a control we treated HemECs with 
5 µM cisplatin for an equivalent amount of time. Cells were 
co-stained with propidium iodide (which only stains the nuclei 
Figure 1. β-adrenergic receptor expression on infantile hemangioma (IH) and 
normal endothelial cells. RT-PCR expression assays measuring the steady 
state levels of ADRB1, ADRB2, and ADRB3 mRNA in primary cultures 
of human infantile hemangioma endothelial cells (HemECs), human dermal 
microvascular endothelial cells (HDMVECs) and human coronary artery 
endothelial cells (HCAECs). Expression data are represented as the relative 
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of dead cells) and Hoechst dye (which stains the nuclei of 
both live and dead cells). Calculation of the apoptotic index 
from each treatment revealed that 50 µM propranolol did not 
induce apoptosis of any of the cell lines tested, while 5 µM 
cisplatin resulted in almost 100% apoptosis (Fig. 3A and B). 
We did observe significant apoptosis in all of our cell lines at 
concentrations of propranolol higher than 150 µM (data not 
shown). To confirm our observations, we utilized western blot-
ting to detect the cleavage products of the apoptotic initiator 
caspase-9 and the apoptotic effector caspase-3. Our data 
indicate that while 5 µM cisplatin strongly induced caspase 
cleavage, 50 µM propranolol failed to induce apoptotic 
signaling (Fig. 3C).
Propranolol disrupts cell migration and actin cytoskeleton 
dynamics. Several reports have presented mixed results for 
the role of β-adrenergic receptor signaling in wound healing 
and cell migration, with evidence that inhibition of this 
class of receptors delays (16-19) or promotes (20-22) wound 
healing. Moreover, in cultured bovine aortic endothelial cells, 
β-adrenergic blockade with propranolol reportedly inhibits 
norepinephrine-induced induction of actin stress fibers (8), 
thus we sought to determine if similar effects on cell migration 
and cytoskeletal organization could be observed in HemECs 
treated with propranolol. HemECs, HDMVECs and HCAECs 
were grown to confluence, manually scratch wounded with a 
micropipette tip, and imaged using time lapse microscopy over 
a period of 12 h. As illustrated in Fig. 4A, treatment of HemECs 
with 50 µM propranolol resulted in a significant reduction in 
‘wound’ closure compared to the control. Quantification of 
the time lapse images taken from the scratch migration assay 
revealed that propranolol dramatically reduced the migratory 
Figure 2. Propranolol decreases the proliferation of human infantile hemangioma endothelial cells (HemECs). (A) HemECs, human dermal microvascular 
endothelial cells (HDMVECs), and human coronary artery endothelial cells (HCAECs) were treated with a dose curve of propranolol (0 to 100 µM) and cell 
proliferation was measured by counting changes in the number of cells/defined vision field over a 48-h period. (B) Time lapse microscopy image of sham 
and 50 µM propranolol treated HemECs over a 48-h period. (C) DNA content analysis of propidium iodide stained HemECs treated with sham or 50 µM 
propranolol for 48 h. (D) Western blot analysis detecting the levels of phosphorylated and total vascular endothelial growth factor receptor-2 (p-VEGFR-2 and 
VEGFR-2, respectively) and the phosphorylated forms of p38 (p-p38), p44 (p-p44), p42 (p-p42), stress activated protein kinase (p-SAPK), c-jun N-terminal 
kinase (p-JNK), and activating transcription factor 4 (p-ATF4) in HemECs treated for 24 h with sham or 50 µM propranolol. Actin levels were used as a loading 
control. (E) Western blot analysis detecting the levels of cyclins, cyclin dependent kinases, and cyclin dependent kinase inhibitors in HemECs treated for 24 h 
with sham or 50 µM propranolol. Actin levels were used as a loading control. Prop, propranolol.
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speed of HemECs (34% reduction), HMVECs (66% reduc-
tion) and HCAECs (67% reduction) (Fig. 4B), suggesting 
that propranolol is more effective at blocking proliferation of 
normal endothelial cells than HemECs. To identify signaling 
events that might shed light on how propranolol disrupts 
migration, we performed western blot analysis to detect the 
activation status of several known regulators of actin cyto-
skeletal dynamics including focal adhesion kinase (FAK), 
cofilin, ezrin/radixin/moesin (ERM), and myosin phospha-
tase (MYPT1), revealing that this drug effectively decreases 
the inhibitory phosphorylation of cofilin (an actin severing 
protein) at serine-3 (Fig. 4C). Given the increased activation 
of cofilin following propranolol treatment, we suspected that 
changes in the actin microfilament cytoskeleton would ensue. 
Indeed, immunofluorescent detection of actin stress fibers 
revealed that propranolol markedly inhibits actin polymeriza-
tion in HemECs (Fig. 4D) and normal endothelial cells (data 
not shown) consistent with that expected from activation of 
cofilin. Computational analysis of actin stress fiber length using 
the FiberScore algorithm (Lichtenstein) demonstrated that 
propranolol-treated HemECs exhibit a greater than 1.5-fold 
reduction in average fiber length compared to the sham treat-
ment (data not shown). Similar observations were observed for 
non-hemangioma endothelial cells (data not shown). In addi-
tion to altering actin stress fiber polymerization, propranolol 
shifted the subcellular localization of p-FAK from regions of 
colocalization with actin stress fibers in sham-treated cells to 
diffuse punctuate regions located throughout the cytoplasm 
in propranolol-treated cells (Fig. 4D). Despite alterations in 
p-FAK subcellular localization, no changes in the levels of 
p-FAK were observed in response to propranolol (Fig. 4C).
Propranolol disrupts global gene expression patterns in 
endothelial cells. Propranolol has been shown to affect the 
expression of cyclins across multiple cell types (5,23), gluco-
Table I. Percentage of endothelial cells in each cell cycle phase.
Cells  Sham Propranolol
HemECs
  G1  68±2.3  74±2.2
  S    8±0.6    5±0.3
  G2/M  24±2.7  21±1.1
HDMVECs
  G1  69±3.0  75±1.6
  S    8±4.1  4±0
  G2/M  22±3.9  20±4.5
HCAECs
  G1  71±1.4  76±1.7
  S    5±1.6    3±1.3
  G2/M  23±3.3  20±2.5
HemECs, human infantile hemangioma endothelial cells; HDMVECs, 
human dermal microvascular endothelial cells; HCAECs, human 
coronary artery endothelial cells.
Figure 3. Propranolol does not induce apoptosis in human infantile hemangioma endothelial cells (HemECs) at its effective inhibitory concentration. 
(A) Confocal imaging of HemECs treated for 72 h with sham or 50 µM propranolol and subsequently co-stained with propidium iodide (PI) and Hoechst dye 
(blue, Hoechst-positive nuclei; pink, Hoechst-positive/PI-positive nuclei). (B) Quantification of PI-positive nuclei in HemECs, human dermal microvascular 
endothelial cells (HDMVECs), and human coronary artery endothelial cells (HCAECs) treated for 72 h with sham or 50 µM propranolol. (C) Western blot 
analysis detecting the levels of cleaved caspase-9 and -3 (cl-caspase-9 and cl-caspase -3, respectively). Actin levels were used as a loading control.
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neogenic and glycolytic enzymes in the liver (24), epidermal 
growth factor 1 in cardiomyocytes (25) and pigment epithe-
lial derived factor in the retina (26). However, these studies 
have focused on small subsets of genes and did not look at 
large-scale changes in genomic expression patterns. To 
evaluate the global gene expression changes in HemECs in 
response to propranolol and to examine how the identified 
changes compared with those observed in propranolol-treated 
normal human endothelial cells, we performed whole genome 
microarrays providing coverage for more than 47,000 
transcripts and known splice variants across the human 
transcriptome. Our analysis identified 89 genes whose expres-
sion in HemECs was altered greater than 2-fold (p<0.05) in 
response to propranolol (32 genes significantly upregulated 
and 57 genes downregulated) (Table II). Several functional 
groupings of genes were identified included those involved 
in lipid and sterol metabolism (21% of total gene expression 
changes: HMGCS1, MSMO1, LDLR, DHCR7, SCD, ACAT2, 
Figure 4. Propranolol disrupts HIHEC migration and actin cytoskeleton dynamics. (A) Confluent monolayers of human infantile hemangioma endothelial 
cells (HemECs) were scratch wounded and treated with sham or 50 µM propranolol. Progress of migration was monitored using time lapse photography over 
a period of 12 h. (B) Quantification of the speed (µm/h) of HemECs, human dermal microvascular endothelial cells (HDMVECs), and human coronary artery 
endothelial cells (HCAECs) treated with sham or propranolol from the time lapse images of the scratch assay. (C) Western blot analysis detecting the levels 
of the total and phophorylated (p-) forms of focal adhesion kinase (FAK), cofilin, ezrin/radixin/moesin (ERM), and myosin phosphatase-targeting subunit 1 
(MYPT1) in HemECs treated with sham or 50 µM propranolol for 48 h. Actin levels were used as a loading control. (D) Confocal immunofluorescent imaging 
of sham or 50 µM propranolol-treated HemECs co-stained with Rhodamine conjugated phalloidin (red), DAPI (blue), and antibodies against phospho-FAK. 
Prop, propranolol.
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Table II. Alterations in gene expression (fold-change) induced by propranolol treatment.
Gene symbol  Gene name  Accession no.  HIHEC  HDMVEC  HCAEC
HMGCS1  3-Hydroxy-3-methylglutaryl-CoA synthase 1  NM_002130.6  4.6  5.8  6.2
MSMO1  Methylsterol monooxygenase 1, TV2  NM_001017369.2  4.5  4.0  5.8
INSIG1  Insulin induced gene 1  NM_198336.2  4.3  4.6  4.9
LDLR  Low density lipoprotein receptor  NM_000527.4  3.6  3.8  3.9
MVD  Mevalonate decarboxylase  NM_002461.1  3.6  5.7  3.4
DHCR7  7-Dehydrocholesterol reductase  NM_001360.2  3.6  4.7  3.4
SCD  Stearoyl-CoA desaturase  NM_005063.4  3.3  3.2  5.0
ACAT2  Acetyl-CoA acetyltransferase 2  NM_005891.2  3.2  4.6  5.2
LSS  Lanosterol synthase  NM_002340.5  3.2  4.5  5.1
TM7SF2  Transmembrane 7 superfamily member 2  NM_003273.2  3.0  4.8  5.2
HMGCR  3-Hydroxy-3-methylglutaryl-CoA reductase  NM_000859.2  2.9  3.1  3.8
FASN  Fatty acid synthase  NM_004104.4  2.8  4.6  4.3
MSMO1  Methylsterol monooxygenase 1, TV1  NM_006745.4  2.8  2.0  3.0
SQLE  Squalene epoxidase  NM_003129.3  2.7  2.6  3.6
PSG4  Pregnancy specific β-1-glycoprotein 4  NM_002780.3  2.6  1.3  4.5
DHCR24  24-Dehydrocholesterol reductase  NM_014762.3  2.5  2.4  3.3
FDFT1  Farnesyl-diphosphate farnesyltransferase 1  NM_004462.3  2.5  2.2  3.2
IDI1 Isopentenyl-diphosphate  δ isomerase 1  NM_004508.2  2.4  2.3  3.4
FADS2  Fatty acid desaturase 2  NM_004265.2  2.4  4.2  2.8
NPC1  Niemann-Pick disease, type C1  NM_000271.4  2.3  2.3  3.8
PFKFB4  Fructose-2,6-biphosphatase 4  NM_004567.2  2.2  2.8  2.3
ACSS2  Acyl-CoA synthetase family member 2, TV2  NM_001076552.2  2.2  2.6  3.5
ACSS2  Acyl-CoA synthetase family member 2, TV1  NM_018677.3  2.2  2.7  3.2
EBP  Emopamil binding protein  NM_006579.2  2.1  2.4  2.3
LOC100129668 LOC100129669  XM_001713607.1  2.1  2.2  2.5
HMOX1  Heme oxygenase (decycling) 1  NM_002133.2  2.1  2.1  3.5
SC5DL  Sterol-C5-desaturase-like  NM_006918.4 2.1  1.4 2.4
NSDHL  NAD(P) dependent steroid dehydrogenase-like  NM_015922.2  2.1  2.3  2.2
P2RX4  Purinergic receptor P2X, 4  NM_002560.2  2.1  1.7  1.8
LPIN1  Lipin 1  NM_145693.1  2.0  1.6  2.9
PGF  Placental growth factor  NM_002632.5  2.0  1.7  2.3
ANGPT2  Angiopoietin 2  NM_001147.2  2.0  1.0  2.1
LOC729009 LOC729010  XR_042330.1  2.0  1.6  2.6
IL8  Interleukin 8  NM_000584.3  -2.0  -2.9  -3.1
CDK1  Cyclin-dependent kinase 1  NM_001786.4  -2.0  -1.8  -2.1
TUBB2C Tubulin,  β 4B Ivb  NM_006088.5  -2.0  -1.4  -2.5
PTTG1  Pituitary tumor-transforming 1  NM_004219.2  -2.0  -2.0  -2.0
OIP5  Opa interacting protein 5  NM_007280.1  -2.0  -2.3  -2.1
CDCA8  Cell division cycle associated 8  NM_018101.3   2.0  -1.4  -2.3
TAGLN  Transgelin  NM_003186.3 -2.0  -1.7 -2.9
CDKN3  Cyclin-dependent kinase inhibitor 3  NM_005192.3  -2.0  -1.7  -1.6
ANLN  Anillin, actin binding protein  NM_018685.2  -2.0  -1.8  -1.7
HJURP  Holliday junction recognition protein  NM_018410.3  -2.0  -1.2  -2.0
PBK  PDZ binding kinase  NM_018492.2  -2.0  -1.6  -2.5
UBE2T  Ubiquitin-conjugating enzyme E2T (putative)  NM_014176.3  -2.0  -1.4  -1.5
STEAP1  6-Transmembrane epithelial antigen of the prostate 1  NM_012449.2  -2.0  -1.8  -1.8
UBE2C  Ubiquitin-conjugating enzyme E2C, TV3  NM_181800.1  -2.0  -1.9  -2.8
CKS1B  CDC28 protein kinase regulatory subunit 1B  NM_001826.2  -2.0  -1.6  -1.9
TACC3  Transforming, acidic coiled-coil containing protein 3  NM_006342.2  -2.0  -1.4  -1.8
NCAPG  Non-SMC condensin I complex, subunit G  NM_022346.3  -2.0  -1.7  -1.6
PCDH7  Protocadherin 7  NM_002589.2  -2.0  -1.2  -2.2
FAM64A  Family with sequence similarity 64, member A  NM_019013.2  -2.1  -1.2  -2.0
PRC1  Protein regulator of cytokinesis 1  NM_199413.1  -2.1  -1.5  -2.3
MELK  Maternal embryonic leucine zipper kinase  NM_014791.3  -2.1  -1.8  -2.1
TPX2  TPX2, microtubule-associated  NM_012112.4  -2.1  -1.4  -2.2
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LSS, FASN, MSMO1, SQLE, DHCR24, FDFT1, IDI1, FADS2, 
ACSS2, EBP, SC5DL, NSDHL and LPIN1), cell cycle regula-
tion (14% of total gene expression changes: CDC2, CDCA8, 
CDKN3, PRC1, MCM4, CDC20, CDC45L, CCNA1, CCNB2, 
CCNA2, TOP2A and CDCA7), angiogenesis (5% of total 
gene expression changes: PGF, ANGPT2, ANGPTL4 and 
RGS4) and ubiquitin modifications (3% of total gene expres-
sion changes: UBE2T, UBE2C and UHRF1). Comparative 
analysis of genes whose expression was statistically altered by 
propranolol treatment in any of the three endothelial cell line 
tests revealed a strong correlation between cell lines (Fig. 5A). 
This data indicate that propranolol-induced gene expression 
changes are endothelial cell-type independent. Quantitative 
RT-PCR validation of ~14% of the propranolol-responsive 
genes in HemECs revealed comparable alterations in gene 
expression similar to that revealed by microarray analysis, 
thus corroborating our microarray data through independent 
analysis (Fig. 5B).
Discussion
IHs as a whole are largely understudied considering the high 
prevalence of these lesions in children and the serious threat to 
health they pose in certain instances. To date, there remains a 
great deal of uncertainty as to the origin of these tumors, with 
evidence suggesting they may be caused by aberrant transplan-
tation of placental endothelial cells (27), predisposing genetic 
factors (28,29) and/or tumor stem cell components (30). 
Despite the controversial origin of these tumors, proliferating 
IHs are characterized by an enhanced angiogenic capacity 
largely due to modulation of signaling pathways that regulate 
the VEGF signaling axis, while involuting IHs display a 
chronic inflammatory response and downregulation of angio-
genesis regulators (31). The recent discovery that the β blocker 
propranolol is an effective treatment for IHs suggests that the 
sympathetic nervous system may play a key role in control-
ling IH growth. Epinephrine is a sympathomimetic amine 
Table II. Continued.
Gene symbol  Gene name  Accession nο.  HIHEC  HDMVEC  HCAEC
ZWINT  ZW10 interactor  NM_001005413.1  -2.1  -1.5  -2.0
KIFC1  Kinesin family member C1  NM_002263.2  -2.1  -1.4  -2.2
CDC20  Cell division cycle 20  NM_001255.2  -2.2  -2.0  -4.0
UBE2C  Ubiquitin-conjugating enzyme E2C, TV6  NM_181803.1  -2.2  -1.8  -2.4
NCAPG2  Non-SMC condensin II complex, subunit G2  NM_017760.5  -2.2  -1.3  -1.4
SERPIND1  Serpin peptidase inhibitor, clade D, member 1  NM_000185.3  -2.2  -1.8  -2.6
CDC45L  Cell division cycle 45  NM_003504.3  -2.2  -1.8  -3.0
LYAR  Ly1 antibody reactive  NM_017816.2  -2.2  -1.6  -1.3
CCNA1  Cyclin A1  NM_003914.3  -2.2  -2.2  -1.9
TRIP1  Thyroid hormone receptor interactor 13  NM_004237.3  -2.2  -1.9  -2.6
MPZL2  Myelin protein zero-like 2, TV2  NM_144765.2  -2.2  -1.3  -2.4
CEP55  Centrosomal protein 55kDa  NM_018131.4  -2.2  -2.0  -2.1
CXCL1  Chemokine (C-X-C motif) ligand 1  NM_001511.3  -2.2  -2.5  -2.8
CCNB2  Cyclin B2  NM_004701.3  -2.2  -2.2  -2.3
KIF20A  Kinesin family member 20A  NM_005733.2  -2.2  -1.9  -2.5
RAD51AP1  RAD51 associated protein 1  NM_006479.4  -2.2  -1.6  -2.2
GINS2  GINS complex subunit 2  NM_016095.2  -2.2  -1.7  -2.9
FAM83D  Family with sequence similarity 83, member D  NM_030919.2  -2.3  -1.6  -2.4
KIAA0101 KIAA0101  NM_014736.4  -2.3  -2.0  -2.3
DLGAP5  Discs, large (Drosophila) homolog-associated protein 5  NM_014750.4  -2.3  -2.0  -2.3
CCNA2  Cyclin A2  NM_001237.3  -2.3  -2.2  -2.8
LOC399942 LOC399943  XM_934471.1  -2.3  -2.4  -3.4
MPZL2  Myelin protein zero-like 2, TV1  NM_005797.3  -2.3  -2.7  -2.2
TOP2A  Topoisomerase II α 170kDa  NM_001067.3  -2.3  -2.4  -2.6
RRM2  Ribonucleotide reductase M2  NM_001034.3  -2.3  -1.5  -2.8
FBXO5  F-box protein 5  NM_012177.3  -2.4  -1.9  -2.6
CDCA7  Cell division cycle associated 7  NM_031942.4  -2.4  -1.9  -2.5
MCM4  Minichromosome maintenance complex CMPT 4, TV1  NM_005914.3  -2.4  -1.5  -2.0
MAD2L1  MAD2 mitotic arrest deficient-like 1  NM_002358.3  -2.4  -2.3  -2.1
UHRF1  Ubiquitin-like with PHD and ring finger domains 1  NM_001048201.1  -2.5  -1.6  -2.6
ANGPTL4  Angiopoietin-like 4  NM_139314.1  -2.8  -2.8  -2.9
RGS4  Regulator of G-protein signaling 4  NM_005613.5  -3.0  -3.8  -3.8
IL1RL1  Interleukin 1 receptor-like 1  NM_003856.2  -3.2    3.4  -5.2
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that increases the activity of noradrenaline in post-synaptic 
cells, and is capable of enhancing vasodilation through activa-
tion of β-adrenergic receptors. β-adrenergic receptors have 
been shown to be expressed on normal capillary endothelial 
cells (32) and it is believed that β blockers, such as propranolol, 
inhibit epinephrine signaling through inducing vasoconstric-
tion of endothelial cells and disruptions in key angiogenic 
processes (7-9,33). Moreover, β blockers have been shown to 
reduce the expression of VEGF in non-endothelial cells, thus 
leading to inhibition of angiogenic paracrine signaling (34). 
Despite the extensive use of propranolol in the treatment of 
IHs, very little has been done to determine the molecular 
mechanisms of propranolol in IH tumors. This drug is 
presumably believed to induce IH tumor regression through 
mechanisms similar to that noted in normal endothelial cells, 
and recent reports suggest that it may work in part through 
suppressing production of nitric oxide and HIF1α regulation 
of VEGF expression (10,11). In this study, we sought to inves-
tigate how propranolol disrupts HIHEC function and compare 
these effects to those seen in normal primary endothelial cell 
lines. Our data demonstrated that β-adrenergic receptors are 
expressed across a panel of HIHEC and normal endothelial 
cells. We further showed that propranolol disrupts HIHEC 
and normal endothelial cell cycle progression, migration, 
cytoskeletal dynamics, and gene expression, and we elucidated 
multiple downstream targets of propranolol including cell 
cycle progression regulators, cytoskeletal modulators and gene 
expression alterations.
The expression of β1- and β2-adrenergic receptors has 
been extensively studied in the cardiovascular system, with 
high expression occurring in cardiac myocytes and vascular 
smooth muscle cells (35). Although β3-knockout mice display 
increased hypotension in response to isoproternol (36), these 
receptors are suspected to play a lesser role in cardiovascular 
function compared to β1- and β2- receptors as they are 
expressed primarily in brown adipocytes, gallbladder and the 
colon (37). Our data indicate that both β1- and β2- (but not 
β3-) adrenergic receptors are expressed on primary cultures 
of HemECs. Interestingly, comparisons of the relative mRNA 
expression levels of these receptors on primary cultures of 
non-diseased endothelial cells revealed similar levels to that 
of HemECs, causing us to question if propranolol is selective 
for HemECs or if this drug demonstrates a similar level of 
inhibition for diseased and normal endothelial cells. Indeed, 
comparisons of the inhibitory effect of propranolol at its IC50 
on cultures of HemECs, HDMVECs, and HCAECs revealed 
that this drug indiscriminately blocks proliferation, migration, 
and actin polymerization in an endothelial cell-type inde-
pendent manner. This finding suggests that the mechanism 
of action for propranolol on IHs may extend beyond simply 
blocking endothelial cell function. For instance, IHs display 
a high pericyte density in the proliferating stage (38) and 
increased molecular markers of endothelial cell/pericyte inter-
actions (31). Primary cultures of pericytes express functional 
adrenergic receptors and respond to autonomic vasoactive 
substances in vivo (39). As pericytes are responsible for a 
number of roles in the microvasculature including capillary 
maturation and stabilization, further studies should examine 
if propranolol inhibits IH growth through destabilization of 
endothelial cell/pericyte interactions. Another possibility that 
may account for the endothelial cell-type independent action 
of propranolol may have to do with the limitations of in vitro 
monolayer cell culture systems. Children undergoing systemic 
propranolol treatment for IHs often undergo side effects 
including bradycardia, hypotension and hypoglycemia (40), 
however significant disruptions of their existing vascular beds 
have not been reported. This suggests that propranolol may 
preferentially inhibit proliferating endothelial vasculature 
while sparing the quiescent established vasculature. However, 
this possibility is complicated by reports suggesting that 
propranolol improves wound healing - a process intimately 
dependent on neovascularization (20-22).
There is evidence that VEGFR-2 phosphorylation is 
controlled by β-adrenergic signaling (5,41,42), however the 
mechanisms underlying this effect remain to be determined. 
As HemECs are characterized by aberrant constitutive activa-
Figure 5. Propranolol induces significant alterations in global gene expression 
of human infantile hemangioma endothelial cells (HemECs). (A) Correlation 
map comparing the significant gene expression changes (>2 fold gene expres-
sion alteration, p<0.05) as determined by microarray analysis between 
HemECs, human dermal microvascular endothelial cells (HDMVECs), and 
human coronary artery endothelial cells (HCAECs) treated with sham or 
50 µM propranolol for 24 h. (B) RT-PCR confirmation of a subset of genes in 
HemECs whose expression was statistically altered in the microarray.
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tion of VEGFR-2 signaling, we sought to determine whether 
propranolol is capable of attenuating this process. Similar to 
data reported in normal endothelial lines, propranolol effec-
tively blocks VEGFR-2 phosphorylation on HemECs. We 
tested the effects of propranolol on known downstream targets 
of VEGF signaling revealing propranolol-induced alterations 
in p38 signaling, decreased cyclin expression and increased 
cyclin-dependent kinase inhibitor steady state mRNA levels. 
Moreover, propranolol treatment of the panel of endothelial 
cells resulted in reduced proliferation rates and increased 
percentages of cells in the G1 cell cycle phase. These altera-
tions were coincident with significant changes in the levels 
of key cyclins and cell cycle inhibitors. Interestingly, of the 
panel of MAPK proteins that we tested, we saw increased 
phosphorylation only in p38, which is known to be responsive 
to stress stimuli such as cytokines, irradiation and shock. 
p38 plays a central role in inflammation and regulates the 
production of inflammatory mediators such as TNFα, IL1β, 
and COX2 (43), thus it is possible that increased p38 activa-
tion in propranolol-treated IHs may mediate IH regression 
through immune-mediated responses. A number of studies 
suggest that propranolol may induce apoptosis of HemECs. 
No caspase cleavage or apoptosis was observed at the IC50 
(~50 µM) for propranolol in HemECs or normal endothelial 
cells, although we did begin to see lethal effects of this treat-
ment in all three endothelial cell lines at upwards of 150 µM. 
These findings do not rule out that propranolol-induced IH 
apoptosis plays a role in the efficacy of this treatment, but it 
does suggest that basic endothelial functions such as prolifera-
tion and migration display greater susceptibility to lower doses 
of propranolol than does apoptosis. We demonstrated that 
propranolol treatment of HemECs results in abolished stress 
fiber formation, and this effect may be due in part to decreased 
levels of phosphorylated cofilin following propranolol treat-
ment. Cofilin is a cytoskeletal-binding protein critical for actin 
microfilament dynamics and reorganization by severing and 
depolymerizing actin filaments (44). Cofilin phosphorylation 
is an inhibitory event (45), thus the absence of stress fiber 
formation observed in propranolol-treated HemECs may be 
due in part to increased cofilin-mediated actin severing. This 
effect would certainly disrupt cell migration, and as the actin 
cytoskeleton is intimately tied to the regulation of cell cycle 
progression (46), may indirectly contribute to propranolol 
induced decreased cell proliferation.
As propranolol appears to work with great efficacy against 
IHs, similar inhibitory effects could potentially be observed 
in other vascular tumors such as angiosarcomas and Kaposi's 
sarcomas. Indeed, propranolol has been tested in preclinical 
and clinical models of malignant tumors, demonstrating good 
efficacy in the treatment of melanoma (47), pancreatic (48), 
colorectal (49) and breast (50) cancer. Finally, given the cuta-
neous nature of IHs and the endothelial cell type-independent 
effects of propranolol observed in our study, topical delivery 
of β blockers (as opposed to systemic delivery) should be 
aggressively pursued. A controlled study of topical adminis-
tration of the β blocker timolol on non-life threatening IHs 
revealed consistently good to moderate responses in 91.5% of 
infants (51), suggesting this therapy could specifically treat the 
lesion area while preventing potential collateral anti-vascular 
effects on the normal endothelium.
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